Solutions OP Clinical Trials UK

The extended access scheme allows patients to have early access to drugs which are not approved on the market but have shown potential in clinical trials. In the UK for the last 10 years were treated over 1,200 patients while in the USA just in 2022 were treated 2,417 patients. Why is that difference? You can learn more from this episode and what could be done to improve access to medications to more patients in the UK.

This episode is dedicated to some of the main challenges that small pharma and biotech companies face. While funding is a critical one there are other issues like selecting the right consultants and vendors and optimising your clinical trials protocols in order to reduce your costs. There is a discussion on some options to optimise the cost of clinical trials.

In this episode are summarised some of the main data protection challenges in artificial intelligence shared during the conference from Information Commissioner's Office.

This episode is dedicated to using placebo in surgical clinical trials; the ethical aspects and what needs to be considered when setting up such clinical trials. Special attention is given to ASPIRE (Applying Surgical Placebo in Randomised Evaluations) guidelines.

This episode is dedicated on real work evidence (RWE) and the benefits and challenges of using such data in research and in support of marketing authorisations. I am also discussing how to improve the quality of real world data when designing your clinical trial.

In this episode I will be talking about placebo clinical trials. I will discuss why we have placebo clinical trials; if they are ethical and what needs to be considered when designing such trials.